Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Recruiting · NCT06238648 · Registry updated 2024-09-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary mediastinal large B-cell lymphoma | Recruiting | Phase 2 | 2024-09-26 | NCT06238648 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Academic and Community Cancer Research United | 13 |
| National Cancer Institute (NCI) | 3015 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hackensack University Medical Center | Hackensack | United States | 308 |
| Huntsman Cancer Institute/University of Utah | Salt Lake City | United States | 249 |
| Mayo Clinic in Rochester | Rochester | United States | 687 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Siteman Cancer Center at Washington University | St Louis | United States | 10 |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | United States | 243 |